<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:chebi fb="0" ids="5959">Irbesartan</z:chebi> is renoprotective in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:mp ids='MP_0002959'>microalbuminuria</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Whether the observed reduction in <z:mp ids='MP_0002959'>microalbuminuria</z:mp> is reversible (hemodynamic) or persistent (glomerular structural/biochemical normalization) after prolonged <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> treatment is unknown </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, the present substudy of the <z:chebi fb="0" ids="5959">Irbesartan</z:chebi> in Patients with Type 2 <z:mp ids='MP_0002055'>Diabetes</z:mp> and <z:mp ids='MP_0002959'>Microalbuminuria</z:mp> Study (IRMA-2) investigated the reversibility of kidney function changes after withdrawal of 2 years' <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> treatment </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: The substudy included 133 hypertensive type 2 diabetic patients with persistent <z:mp ids='MP_0002959'>microalbuminuria</z:mp> in IRMA-2, randomized to double-masked treatment with either placebo, <z:chebi fb="0" ids="5959">irbesartan</z:chebi> 150 mg, or <z:chebi fb="0" ids="5959">irbesartan</z:chebi> 300 mg o.d. for 2 years </plain></SENT>
<SENT sid="4" pm="."><plain>Arterial blood pressure, overnight urinary albumin excretion rate, and glomerular filtration rate (GFR) were determined repeatedly </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Baseline characteristics were similar in the placebo, <z:chebi fb="0" ids="5959">irbesartan</z:chebi> 150-mg, and <z:chebi fb="0" ids="5959">irbesartan</z:chebi> 300-mg groups </plain></SENT>
<SENT sid="6" pm="."><plain>At the end of the study, mean arterial blood pressure (MABP) was similarly lowered to 105 +/- 2 (mean +/- SE), 103 +/- 2, and 102 +/- 2 mmHg, respectively (P &lt; 0.05 versus baseline), and urinary albumin excretion rate reduced by 8% (-16 to 27) (NS), 34% (95% CI 8-53), and 60% (46-70) (P &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>Rates of decline in GFR were 1.3 +/- 0.7, 1.2 +/- 0.7, and 1.0 +/- 0.8 ml </plain></SENT>
<SENT sid="8" pm="."><plain>min(-1) </plain></SENT>
<SENT sid="9" pm="."><plain>1.73 m(-2) per month, respectively, during the initial 3 months of the study and 0.3 +/- 0.1, 0.3 +/- 0.1, and 0.4 +/- 0.1 ml </plain></SENT>
<SENT sid="10" pm="."><plain>min(-1) </plain></SENT>
<SENT sid="11" pm="."><plain>1.73 m(-2) per month in the remaining study period </plain></SENT>
<SENT sid="12" pm="."><plain>One month after withdrawal of <z:hpo ids='HP_0000001'>all</z:hpo> <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> medication, MABP remained unchanged in the placebo group, 105 +/- 2 mmHg, but increased significantly in the <z:chebi fb="0" ids="5959">irbesartan</z:chebi> groups, to 109 +/- 2 and 108 +/- 2 mmHg, respectively </plain></SENT>
<SENT sid="13" pm="."><plain>Compared with baseline, urinary albumin excretion rate was increased by 14% (-17 to 54) in the placebo group and by 11% (-26 to 65) in the <z:chebi fb="0" ids="5959">irbesartan</z:chebi> 150-mg group but was persistently reduced by 47% (24-73) in the <z:chebi fb="0" ids="5959">irbesartan</z:chebi> 300-mg group (P &lt; 0.05) </plain></SENT>
<SENT sid="14" pm="."><plain>GFR levels increased to baseline values in the placebo group and approached initial levels in <z:chebi fb="0" ids="5959">irbesartan</z:chebi> groups </plain></SENT>
<SENT sid="15" pm="."><plain>CONCLUSIONS: Persistent reduction of <z:mp ids='MP_0002959'>microalbuminuria</z:mp> after withdrawal of <z:hpo ids='HP_0000001'>all</z:hpo> <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> treatment suggests that high-dose <z:chebi fb="0" ids="5959">irbesartan</z:chebi> treatment confers long-term renoprotective effects </plain></SENT>
</text></document>